Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 1997

View Archived Issues

EntreMed: Q3 1997 highlights

Olpadronate associated with improvement in osteogenesis imperfecta

Myriad Genetics and Bayer join forces to develop dementia and depression therapies

Cantab: Q3 1997 highlights

Microcide: Q3 1997 highlights

Clinical trial demonstrates efficacy of NPS-R-568 in hyperparathyroidism

Affymetrix: Q3 1997 highlights

Pharmacia & Upjohn: Q3 1997 highlights

GH secretagogues under development at Merck & Co.

Mitsui Norin discovers natural antiviral/antitumor agent

New triazole antifungals from Pfizer

Lilly claims antithrombotic diamides

Takeda reports novel carbapenems

Brain GABA receptor ligands prepared at Neurogen

DCK analogues with potent and selective anti-HIV activity

Role of complement in mast cell-dependent natural immunity

Favorable results obtained in pediatric study of Neuprex

Phase I trial of multiple-dose IDEC-C2B8 in NHL

New NK1 antagonist from Novartis

Six-month trial of lamivudine for chronic hepatitis B

Role of substance P in PTH secretion described

FDA advisory committee recommends approval of Rocephin for AOM

Doxil/Caelyx evaluated in phase II for advanced breast cancer

NK3 antagonist demonstrates intestinal antiinflammatory activity

Palatin receives FDA clearance to start LeuTech clinical trials

Antifungal activity of KP-103 under evaluation

Gel formulation of diclofenac and hyaluronan effective in aphthous ulcer pain

Novartis launches once-monthly formulation of Sandostatin

Combivir recommended for approval in Europe

Development of new quinolone from Toyama advances